MWNA
PRQR icon

Marshall Wace North America’s ProQR Therapeutics PRQR Stock Holding History

Marshall Wace North America’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-712,529
Closed -$4.71M – 1706
2021
Q1 		$4.71M Buy
+712,529
New +$3.64M 0.02% 583
2019
Q4 		– Sell
-20,193
Closed -$116K – 1537
2019
Q3 		$116K Buy
+20,193
New +$161K ﹤0.01% 1037

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Marshall Wace North America's PRQR Position: Q2 2021 in Review

Marshall Wace North America sold out of ProQR Therapeutics (PRQR) in Q2 2021, closing a stake of 712,529 shares — an estimated $4.71M sold.

Marshall Wace North America first reported a position in PRQR in Q3 2019 and held it in 2 quarters. The position peaked at $4.71M in Q1 2021. 63 funds tracked by Wall St. Rank hold PRQR as of Q2 2021.

  • Marshall Wace North America reported no remaining ProQR Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 712,529 ProQR Therapeutics shares in Q2 2021, an estimated $4.71M.
  • Marshall Wace North America first reported a position in ProQR Therapeutics in Q3 2019 and held it in 2 quarters.
  • Marshall Wace North America's ProQR Therapeutics position peaked at $4.71M in Q1 2021.
  • 63 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.